Stock Financial Ratios, Dividends, Split History

ARDM / Aradigm Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.30
Volume61,400.00
Market Cap ($M)19.77
Enterprise Value ($M)18.38
Book Value ($M)-16.71
Book Value / Share-1.10
Price / Book-1.21
NCAV ($M)-17.06
NCAV / Share-1.12
Price / NCAV-1.16
Share Statistics
Common Stock Shares Outstanding 15,170,200
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 15,170,200
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.85
Return on Assets (ROA)-0.43
Return on Equity (ROE)-10.85
Balance Sheet (mrq) ($M)
Assets2.63
Liabilities19.35
Quick Ration/a
Current Ratio0.61
Income Statement (mra) ($M)
Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price4,527,000.00
Royalty Revenue0.00
Contracts Revenue268,000.00
Contracts Revenue Related Party14,075,000.00
Revenue From Grants122,000.00
Revenues14,465,000.00
Operating Income-6.94
Net Income-10.71
Earnings Per Share Basic And Diluted-0.72
Earnings Per Share Basic-0.72
Earnings Per Share Diluted-0.72
Cash Flow Statement (mra) ($M)
Cash From Operations-16.50
Cash from Investing0.85
Cash from Financing-16.50
Identifiers and Descriptors
CUSIP038505400
Central Index Key (CIK)1013238
Related CUSIPS
038505301

Split History

Stock splits are used by Aradigm Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Juniper Pharmaceuticals: Undervalued With Double-Digit Revenue Growth

2018-04-19 seekingalpha
Juniper Pharmaceuticals licensed its leading revenue drug, Crinone, to Merck, with a fixed contract through 2024. (53-5)

Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study

2018-04-06 seekingalpha
Conatus (NASDAQ:CNAT) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNAT’s lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor designed to reduce the activity of human caspases in liver transplant patients with fibrosis or cirrhosis. It is one of the four studies CNAT is currently conducting with its lead product candidates. (351-1)

Aradigm Files MAA for Bronchiectasis Candidate in the EU

2018-03-12 zacks
Aradigm Corporation’s (ARDM - Free Report) shares increased almost 3% on Mar 9 after the company announced submission of marketing authorization application (MAA) to European Medicines Agency (EMA) for its lead candidate, Linhaliq. (27-0)

3 Things In Biotech, March 11: Aradigm Retries, Pfizer Glides, VBL Crashes

2018-03-12 seekingalpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. (16-0)

Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC

2018-03-10 seekingalpha
Today, we will discuss Immuron (IMRN) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in the U.S. (54-4)

CUSIP: 038505400